CC
ADVM

Commodore Capital’s Adverum Biotechnologies ADVM Stock Holding History

Commodore Capital’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-657,333
Closed -$9.29M – 37
2024
Q1 		$9.29M Sell
657,333
-342,667
-34% -$5.21M 0.62% 31
2023
Q4 		$7.53M Hold
1,000,000
– – 0.66% 29
2023
Q3 		$15M Hold
1,000,000
– – 1.75% 19
2023
Q2 		$15.9M Buy
1,000,000
+500,000
+100% +$5.26M 1.79% 18
2023
Q1 		$3.59M Buy
+500,000
New +$3.54M 0.55% 28

Other funds holding ADVM

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

Commodore Capital's ADVM Position: Q2 2024 in Review

Commodore Capital sold out of Adverum Biotechnologies (ADVM) in Q2 2024, closing a stake of 657,333 shares — an estimated $9.29M sold.

Commodore Capital first reported a position in ADVM in Q1 2023 and held it in 5 quarters. The position peaked at $15.9M in Q2 2023. 68 funds tracked by Wall St. Rank hold ADVM as of Q2 2024.

  • Commodore Capital reported no remaining Adverum Biotechnologies position as of Q2 2024 after selling out during the quarter.
  • Commodore Capital sold 657,333 Adverum Biotechnologies shares in Q2 2024, an estimated $9.29M.
  • Commodore Capital first reported a position in Adverum Biotechnologies in Q1 2023 and held it in 5 quarters.
  • Commodore Capital's Adverum Biotechnologies position peaked at $15.9M in Q2 2023.
  • 68 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q2 2024.

Based on Commodore Capital's 13F filing for Q2 2024, filed 14 Aug 2024.